Astellas Pharma Stock News

Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland, January 07, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, announced today that sales of the antifungal Cresemba ® (isavuconazole) by its partner Astellas Pharma Inc. ("Astellas") in the United States exceeded the threshold triggering a milestone payment to Basilea of CHF 15 million. David Veitch, Chief Executive Officer of Basilea, said: "We are very pleased with the continued commercial success of Cresemba. This significant milestone payment reflects the strong sales growth in 2021 in the U.S. and confirms the important role that Cresemba plays in the treatment of patients suffering from invasive mold infections." Under the license agreement with Astellas, Basilea is entitled to receive milestone payments based on Astellas exceeding certain net sales thresholds in the United States within a calendar year.

The global Prostate Cancer Drugs market was valued at 612.86 Million USD in 2020 and will grow with a CAGR of 6.47% from 2021 to 2027. The prostate cancer drugs market comprises different medications utilized for the anticipation and therapy

Latest published market study on Global DTaP and Tdap Vaccines Market provides an overview of the current market dynamics in the DTaP and Tdap Vaccines space, as well as what our survey respondentsall outsourcing decision-makerspredict the market will look like

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) and Seagen Inc. (SGEN) said the CHMP of the European Medicines Agency has adopted a positive opinion, recommending approval

(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) and Seagen Inc. (SGEN) said the CHMP of the European Medicines Agency has adopted a positive opinion, recommending approval of the antibody-drug conjugate PADCEV or enfortumab vedotin, as monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have

- If approved, PADCEV would be the first medicine for patients in the EU who have received prior platinum-based chemotherapy and a PD-1/L1 inhibitor Astellas Pharma Inc. (TSE:4503, President and C

TOKYO & BOTHELL, Wash.--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas) and Seagen Inc. (Nasdaq:SGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of the antibody-drug conjugate (ADC) PADCEV (enfortumab vedotin) as monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 31,200 shares, a decrease of 50.9% from the November 15th total of 63,500 shares. Based on an average trading volume of 140,800 shares, the short-interest ratio is []

Stem Cell Therapy Market 2021 report helps the clients to take business decisions and to understand strategies of major players in the industry. The report also calls for market- driven results deriving feasibility studies for client needs. Market Insights Reports

DUBLIN--(BUSINESS WIRE)--The "Global Spinal Muscular Atrophy Treatment Market (2021-2026) by Disease Type, Treatment, Route of Administration and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com''s offering. The Global Spinal Muscular Atrophy Treatment Market is estimated to be USD 1.1 Bn in 2021 and is expected to reach USD 1.98 Bn by 2026, growing at a CAGR of 12.5%. The SMA treatment market is growing at a signifi

Astellas Pharma Inc. (OTCMKTS:ALPMY)s share price passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $16.89 and traded as low as $15.09. Astellas Pharma shares last traded at $15.59, with a volume of 103,816 shares changing hands. Separately, Zacks Investment Research downgraded Astellas []

DUBLIN--(BUSINESS WIRE)--The "Immunosuppressants Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global immunosuppressants market is expected to grow from $15.04 billion in 2020 to $16.5 billion in 2021 at a compound annual growth rate (CAGR) of 9.7%. The market is expected to reach $25.33 billion in 2025 at a CAGR of 11%. Major players in the immunosuppressant market are Astellas Pharma, GlaxoSmithKline, Bristol Mye

The live attenuated varicella vaccine, derivative from the Oka strain of VZV has clinical effectiveness for the prevention of varicella. The vaccine induces tenacious immunity to VZV in strong children and adults. Immunization against VZV also has the possibility to

Gene therapy startup Dyno Therapeutics Inc has partnered with pharmaceutical giants such as Novartis AG (NYSE: NVS ) and Roche Holdings AG (OTC: RHHBY ). It has added another major biotech, Astellas Pharma Inc (OTC: ALPMY ) Astellas is dishing out $18 million upfront and up to $1.6 billion in milestone and royalty payments to develop adeno-associated virus (AAV) vectors for gene Full story available on Benzinga.com